Arcellx (ACLX) EBIT Margin (2023 - 2025)

Arcellx's (ACLX) quarterly EBIT Margin came in at 3777.16% in Q4 2025, down 342899.0% year-on-year from N/an in Q4 2024, and down 202.6% quarter-over-quarter from 1248.25% in Q3 2025.

Arcellx (ACLX) EBIT Margin (2023 - 2025) Analysis & Trends

Arcellx's EBIT Margin history runs 3 years deep, the most recent figure standing at 3777.16% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 342899.0% year-over-year to 3777.16% in Q4 2025; TTM through Dec 2025 was 1131.65%, a 100420.0% decrease from a year earlier, with the FY2025 full-year figure at 1135.61%, down 100816.0% from the prior year.
  • EBIT Margin slipped to 3777.16% in Q4 2025 per ACLX's latest filing, from 1248.25% in the prior quarter.
  • Across five years, EBIT Margin topped out at 23.75% in Q4 2023 and bottomed at 3777.16% in Q4 2025.
  • The 3-year median for EBIT Margin is 253.31% (2023), against an average of 662.0%.
  • Across the five-year window, EBIT Margin surged 17080 bps in 2024 and tumbled 342899 bps in 2025, its largest moves.
  • Year by year, EBIT Margin stood at 23.75% in 2023, then slumped by 1566 bps to 348.17% in 2024, then sank by 985 bps to 3777.16% in 2025.
  • Per Business Quant, the three latest ACLX EBIT Margin figures stand at 3777.16% (Q4 2025), 1248.25% (Q3 2025), and 772.71% (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 16.51%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 38.10%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 17.83%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 31.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Arcellx 6.48 Bn 6.48 Bn - -3,777.16%

Historic Data

Download Data
DateValue
Dec 31, 2025 -3,777.16%
Sep 30, 2025 -1,248.25%
Jun 30, 2025 -772.71%
Mar 31, 2025 -847.56%
Dec 31, 2024 -348.17%
Sep 30, 2024 -129.14%
Jun 30, 2024 -127.79%
Mar 31, 2024 -40.27%
Dec 31, 2023 23.75%
Sep 30, 2023 -299.94%
Jun 30, 2023 -206.68%
Mar 31, 2023 -170.04%